What the CMS manual actually says about ASC implant billing

The six questions post gave the short answer to whether an ASC bills Medicare separately for an implant: no, with one narrow exception. This is the long version, read from the source rather than from summaries of it.

The sources are short and public. Chapter 14 of the Medicare Claims Processing Manual (revision 13836, issued June 2026), the ASC payment regulations at 42 CFR 416, and the addenda CMS publishes with each quarterly ASC update. Most of what circulates about ASC implant billing stops at “bundled.” That is correct, and it leaves out the parts of the rules where the vendor’s paperwork still decides what gets paid.

The rule: the implant is part of the procedure

Since January 1, 2008, Medicare has treated implants as part of the ASC facility service. The regulation lists what the procedure payment includes, and two entries on that list are implanted prosthetic devices (intraocular lenses included) and implanted DME, with their related accessories and supplies, whenever they are not on pass-through status.

Chapter 14 then says it without qualification: ASCs may not bill separately for implantable devices without OPPS pass-through status.

It did not always work this way. Before 2008, ASCs billed most implantable prosthetic devices separately and were paid from the DMEPOS fee schedule. Some of the billing habits and articles still in circulation date from that system.

A separately billed implant without pass-through status is denied, and the manual specifies exactly how: group code CO, CARC 97, RARC M97 and MSN 16.32, with MSN 16.8 added when an approved surgical procedure for the same date is on file. The group code matters. CO marks the adjustment as the provider’s rather than the patient’s, so the denied implant line is not something the ASC can bill to the beneficiary.

The code most often published for this denial is CARC 96. The manual assigns 96 to a different situation: codes carrying payment indicator E5 or Y5, which are not valid for Medicare purposes at all, and it pairs 96 with group code PR, patient responsibility. A denial workflow built on 96 goes looking for the wrong cause.

Where the implant’s cost belongs on the claim

Packaged does not mean the cost disappears. It moves onto the procedure line.

Chapter 14 tells ASCs to fold the charges for packaged items into the charge for the separately payable procedure they were used in, rather than reporting them as lines of their own. The reason is in how contractors price the claim. Each line is paid on the lower of its submitted charge and its ASC rate, and that comparison happens line by line.

Follow that through. An implant split onto its own line does not only get denied, it can also leave the procedure line priced on a charge that no longer includes it. The manual’s own wording is that facilities “may not be paid appropriately” when they unbundle charges this way.

Device-intensive procedures: still packaged, priced for the device

Some procedures carry so much device cost that Medicare prices them differently. The regulation calls them device-intensive: procedures that surgically insert or implant a device with its own CPT or HCPCS code, and whose code-level device offset is greater than 30 percent. The device offset is CMS’s calculation of how much of the procedure’s hospital outpatient rate is the device.

For those procedures, the device portion of the ASC payment is derived from the hospital outpatient rate instead of going through the ASC’s standard rate-setting with the rest of the procedure. They carry payment indicator J8, which CMS defines as “device-intensive procedure; paid at adjusted rate.”

Two things follow. The implant is still packaged, so there is still no separate implant line. And the threshold cuts through an ordinary orthopedic case mix in places the procedure name does not predict.

• Total hip arthroplasty, 27130 (J8)47.9%
• Total knee arthroplasty, 27447 (J8)44.2%
• ACL reconstruction, 29888 (J8)35.2%
• Rotator cuff repair, 29827 (A2)26.6%

CMS, July 2026 ASC addenda: device offset percentages from Addendum FF, payment indicators from Addendum AA. Above 30 percent a procedure is device-intensive (J8). Rotator cuff repair falls below the line and is priced the standard way (A2). CMS recalculates these percentages in each annual rule.

An ACL reconstruction clears the line. A rotator cuff repair, with its suture anchors, does not. The implant is packaged in both cases, unless that specific device holds pass-through status, which is covered below. What changes is how much of the procedure payment was built around the device, and whether the device-credit modifiers in the next section come into play.

When the device cost the ASC nothing: FB and FC

Devices get recalled, replaced under warranty and credited back. Section 40.8 of Chapter 14 covers what that does to the procedure payment.

• When a specified device is furnished at no cost, or the ASC receives full credit for it, the ASC appends modifier FB to the procedure code.
• When the ASC receives a partial credit of 50 percent or more of the device’s cost, and the procedure is on the list the reduction applies to, it appends modifier FC.
• Never both on one procedure code. The contractor reduces the payment before any multiple-procedure discount, and adjusts the beneficiary’s coinsurance to match.

A partial credit is often unsettled when the claim is ready to go, and the manual allows for that. The ASC can submit the claim, then ask the contractor for an adjustment once the manufacturer decides the credit, on the understanding that the first payment is conditional. Or it can hold the claim until the decision and submit with FC appended.

Either way, the fact that decides the modifier arrives on the manufacturer’s paperwork, not in the operative note. A credit memo lands with whoever manages vendor accounts, and the claim is built in billing. It is the same seam as a missed implant charge, running the other way: the exposure here is a claim that goes out at full price for a device the center got back.

Pass-through devices: the one implant Medicare pays separately

The exception in the rule is the pass-through device. Under the hospital outpatient system, CMS grants new categories of devices transitional pass-through payment, and the ASC system follows it. These carry payment indicator J7, which CMS defines as an “OPPS pass-through device paid separately when provided integral to a surgical procedure on ASC list; payment contractor-priced.”

Contractor-priced is the phrase that matters. The manual says pass-through devices are priced by the Medicare contractor “based on acquisition cost or invoice.” For this one category of implant, the vendor invoice is the price.

The rest of the rules are specific:

• Same claim. A pass-through device goes on the same claim as the procedure it was used in. If no approved ASC procedure for the same patient, provider and date is on the claim or in history, the device line comes back unprocessable, with CARC 16 and RARC M51.
• No double payment. For listed pairs of device and procedure codes, the contractor reduces the procedure payment by the device portion already built into it, then pays the device on its own line.
• Credits go on the device line. FB and FC do not apply to a pass-through device. The ASC reports the credit along with the device’s invoice price, and the line-item charge has to reflect the credit.
• Status expires. By statute, a device category keeps pass-through payment for at least two years and no more than three. After that, its cost is packaged into the procedure like any other implant.

The list is short, and it turns over. The July 2026 addendum carries about twenty pass-through device codes and flags the ones that expire during the year. Orthopedic devices do appear on it: C1741, for example, covers certain absorbable bone anchors and screws. The same quarterly update added a single new device category: C1609, a motion-preserving vertebral device with screw fixation.

Five checks for your own Medicare claims

Each comes straight from a section above.

1. Search your remits for CARC 97 paired with M97. In Chapter 14, that combination is the denial for a separately billed implant. Each one is worth tracing back to its case.
2. Check that procedure line charges carry the implant cost. A packaged item’s charge belongs inside the procedure’s charge, not beside it.
3. Know which of your procedure codes are J8. Addendum AA gives every covered procedure’s indicator each quarter, and device-intensive procedures are where FB and FC come into play.
4. Route device credits to billing. A recall or warranty credit on a device-intensive procedure changes what the claim should say.
5. Watch the quarterly update for pass-through changes. Addendum BB lists every pass-through device and flags the ones whose status expires during the year.

What the manual cannot tell you

Everything above is public, specific, and checkable against a source. That is the difference between Medicare and every commercial contract an ASC holds.

Medicare’s packaging comes with its own pricing logic. The procedure rate is built to include the device, device-intensive procedures get their device portion from the hospital outpatient rate, and the few pass-through devices are paid on invoice. A commercial contract can adopt the packaging without adopting any of the pricing logic that came with it. Whether yours did is written in the contract, and nowhere else.

That is also why Bill-Back works commercial payers only. With Medicare, the implant is part of the procedure payment, so there is nothing separate to recover. The pass-through exception is a short list, priced on the invoice by the contractor and billed on the Medicare claim itself. Medicare Advantage and Medicaid are excluded too.

On the commercial side, Bill-Back reads three documents a center already has: the monthly case log export from the PMS, the vendor invoice PDFs, and the charge entry report. It matches each supply note to its invoice line and prices it at the contracted rate. Someone on the center’s side clears anything already on a claim, and what is left becomes a payer-ready Recoup Packet for the center’s own biller to submit. Free to audit, and you only pay when the payer pays.

You can estimate what the commercial side is worth at your case volume in about thirty seconds, or start a free audit against a month of your own files.

Sources

Every rule and figure above traces to one of these. Each was read in full at the source.

• Medicare Claims Processing Manual, Chapter 14: Ambulatory Surgical Centers, CMS (Rev. 13836, June 2026). Sections 10.2, 10.4, 40, 40.7, 40.8, 60.2 and 60.3.
• 42 CFR 416.164, Scope of ASC services, via eCFR.
• 42 CFR 416.171, Determination of payment rates for ASC services, via eCFR. Paragraph (b)(2) defines device-intensive procedures.
• July 2026 ASC Approved HCPCS Code and Payment Rates, CMS. Addenda AA, BB, DD1 and FF.
• Transmittal 13836, July 2026 Update of the Ambulatory Surgical Center Payment System, CMS Change Request 14522.